Protagenic Short Long Term Debt Total from 2010 to 2024

PTIXW Stock  USD 0.01  0  34.03%   
Protagenic Therapeutics Short and Long Term Debt Total yearly trend continues to be fairly stable with very little volatility. Short and Long Term Debt Total will likely drop to about 294.3 K in 2024. During the period from 2010 to 2024, Protagenic Therapeutics Short and Long Term Debt Total regression line of quarterly data had mean square error of 557.2 B and geometric mean of  482,758. View All Fundamentals
 
Short and Long Term Debt Total  
First Reported
1996-06-30
Previous Quarter
394.3 K
Current Value
419.8 K
Quarterly Volatility
2.1 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Protagenic Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Protagenic Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 26.8 K, Interest Expense of 137.6 K or Selling General Administrative of 1.1 M, as well as many indicators such as Price To Sales Ratio of 0.28, Dividend Yield of 0.0 or PTB Ratio of 1.11. Protagenic financial statements analysis is a perfect complement when working with Protagenic Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Protagenic Therapeutics Correlation against competitors.
For more information on how to buy Protagenic Stock please use our How to Invest in Protagenic Therapeutics guide.

Latest Protagenic Therapeutics' Short Long Term Debt Total Growth Pattern

Below is the plot of the Short Long Term Debt Total of Protagenic Therapeutics over the last few years. It is Protagenic Therapeutics' Short and Long Term Debt Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Protagenic Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Short Long Term Debt Total10 Years Trend
Slightly volatile
   Short Long Term Debt Total   
       Timeline  

Protagenic Short Long Term Debt Total Regression Statistics

Arithmetic Mean790,071
Geometric Mean482,758
Coefficient Of Variation113.37
Mean Deviation725,535
Median309,807
Standard Deviation895,676
Sample Variance802.2B
Range2.4M
R-Value(0.60)
Mean Square Error557.2B
R-Squared0.36
Significance0.02
Slope(119,339)
Total Sum of Squares11.2T

Protagenic Short Long Term Debt Total History

2024294.3 K
2023309.8 K
2022344.2 K
2021318.4 K
20201.4 M
2016279.4 K
2015515 K

About Protagenic Therapeutics Financial Statements

Protagenic Therapeutics investors use historical fundamental indicators, such as Protagenic Therapeutics' Short Long Term Debt Total, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Protagenic Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Short and Long Term Debt Total309.8 K294.3 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Protagenic Stock Analysis

When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.